The Oncology Institute, Inc. (DFPH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1250886,
    "name": "The Oncology Institute, Inc.",
    "stock_name": "The Oncology Institute, Inc.",
    "full_name": "The Oncology Institute, Inc.",
    "name_url": "stocks-analysis/the-oncology-institute-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "3.23",
    "chg": 0.27,
    "chgp": "9.12%",
    "dir": 1,
    "prev_price": "2.96",
    "mcapval": "303.89",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 3365,
    "indexname": "S&P 500",
    "isin": "US68236X1000",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "4.0 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/the-oncology-institute-inc-1250886-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is The Oncology Institute, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-the-oncology-institute-inc-technically-bullish-or-bearish-3548435",
        "imagepath": "",
        "date": "2025-09-20 20:17:34",
        "description": "As of 25 August 2025, the technical trend for The Oncology Institute, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the weekly MACD and KST show mildly bearish signals. The monthly MACD and KST are bullish, and Bollinger Bands reflect a bullish to mildly bullish trend across time frames. However, the weekly RSI shows no signal and the monthly RSI is bearish, indicating some weakness.\n\nIn terms of performance, the company has significantly outperformed the S&P 500 year-to-date with a return of 948.54% compared to the S&P 500's 12.22%, but it has underperformed over the longer 3-year and 5-year periods...."
      },
      {
        "title": "Is The Oncology Institute, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-the-oncology-institute-inc-overvalued-or-undervalued-3544461",
        "imagepath": "",
        "date": "2025-09-20 18:47:02",
        "description": "As of 10 May 2023, the valuation grade for The Oncology Institute, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its significant negative ratios, including a Price to Book Value of 48.83 and an EV to EBITDA of -6.34. Additionally, its ROCE stands at a troubling -113.07%, reflecting severe inefficiencies in capital utilization.\n\nIn comparison to its peers, The Oncology Institute's EV to EBITDA ratio of -8.88 is considerably worse than Nutex Health, Inc., which has a very attractive EV to EBITDA of 1.88, highlighting a stark contrast in operational performance. Other risky peers like LifeMD, Inc. and The Joint Corp. also exhibit negative EV to EBITDA ratios, but none approach the extreme levels seen with The Oncology Institute. Despite a remarkable year-to-date stock return of 948.54%, which si..."
      }
    ],
    "total": 6,
    "sid": "1250886",
    "stock_news_url": "https://www.marketsmojo.com/news/the-oncology-institute-inc-1250886"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is The Oncology Institute, Inc. technically bullish or bearish?

2025-09-20 20:17:34

As of 25 August 2025, the technical trend for The Oncology Institute, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the weekly MACD and KST show mildly bearish signals. The monthly MACD and KST are bullish, and Bollinger Bands reflect a bullish to mildly bullish trend across time frames. However, the weekly RSI shows no signal and the monthly RSI is bearish, indicating some weakness. In terms of performance, the company has significantly outperformed the S&P 500 year-to-date with a return of 948.54% compared to the S&P 500's 12.22%, but it has underperformed over the longer 3-year and 5-year periods....

Is The Oncology Institute, Inc. overvalued or undervalued?

2025-09-20 18:47:02

As of 10 May 2023, the valuation grade for The Oncology Institute, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its significant negative ratios, including a Price to Book Value of 48.83 and an EV to EBITDA of -6.34. Additionally, its ROCE stands at a troubling -113.07%, reflecting severe inefficiencies in capital utilization. In comparison to its peers, The Oncology Institute's EV to EBITDA ratio of -8.88 is considerably worse than Nutex Health, Inc., which has a very attractive EV to EBITDA of 1.88, highlighting a stark contrast in operational performance. Other risky peers like LifeMD, Inc. and The Joint Corp. also exhibit negative EV to EBITDA ratios, but none approach the extreme levels seen with The Oncology Institute. Despite a remarkable year-to-date stock return of 948.54%, which si...

View All News